Travere Therapeutics (NASDAQ:TVTX) Insider Jula Inrig Sells 311 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 311 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total value of $13,668.45. Following the completion of the sale, the insider directly owned 113,238 shares of the company’s stock, valued at $4,976,810.10. This represents a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Tuesday, May 5th, Jula Inrig sold 2,174 shares of Travere Therapeutics stock. The shares were sold at an average price of $46.65, for a total value of $101,417.10.
• On Monday, May 4th, Jula Inrig sold 20,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $45.00, for a total value of $900,000.00.
• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The shares were sold at an average price of $42.61, for a total value of $43,376.98.
• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The shares were sold at an average price of $41.93, for a total value of $302,524.95.

Travere Therapeutics Stock Down 0.2%

TVTX opened at $44.70 on Thursday. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70. The business has a 50 day simple moving average of $32.59 and a 200-day simple moving average of $32.83. The stock has a market capitalization of $4.16 billion, a P/E ratio of -194.33 and a beta of 1.13. Travere Therapeutics, Inc. has a 12 month low of $13.88 and a 12 month high of $48.61.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.29. The business had revenue of $127.20 million during the quarter, compared to analysts’ expectations of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The company’s quarterly revenue was up 55.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.47) EPS. On average, equities analysts anticipate that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target to $60 and keeps a “buy” rating — a large upside from the recent price that supports buying interest and likely helped lift the stock. Article Title
• Positive Sentiment: Wells Fargo raised its price target to $50 and moved to an “overweight” rating — another bullish analyst signal adding demand. Article Title
• Positive Sentiment: Recent Q1 results (reported May 4) showed an EPS beat and ~55.6% revenue growth year?over?year, providing fundamental support for the analyst upgrades and investor optimism. No link
• Neutral Sentiment: Travere priced an upsized $475.0M offering of 0.50% convertible senior notes due 2032 (up from $400M). This extends maturity and raises liquidity but carries potential future dilution if converted; the deal closes subject to conditions on May 11. Article Title
• Neutral Sentiment: HC Wainwright slightly trimmed long?term EPS forecasts (FY2027–FY2030) but maintains a “Buy” rating and a $57 target — small model tweaks that didn’t remove analyst support. No link
• Neutral Sentiment: Transcript of the Q1 2026 earnings call is available for detail review if you want management color on growth drivers and use of proceeds from the notes offering. Earnings Call Transcript
• Negative Sentiment: Multiple insiders — including the CEO, several directors and executives — sold shares recently (large transactions disclosed via Form 4s). While the company says many sales were executed under pre?arranged Rule 10b5?1 plans and to cover tax withholding on awards, the volume (notably the CEO’s 22,500?share sale) can create short?term selling pressure or investor concern. Example SEC filing: CEO Form 4

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on TVTX shares. TD Cowen raised their price objective on Travere Therapeutics from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday. Wedbush raised their price objective on Travere Therapeutics from $53.00 to $55.00 and gave the company an “outperform” rating in a research note on Tuesday. HC Wainwright raised their price objective on Travere Therapeutics from $47.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. dropped their price objective on Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a research note on Wednesday, March 25th. Finally, Wells Fargo & Company raised their price objective on Travere Therapeutics from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $47.83.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds have recently bought and sold shares of TVTX. Emerald Advisers LLC increased its position in Travere Therapeutics by 2.6% during the third quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company’s stock worth $51,308,000 after buying an additional 55,407 shares in the last quarter. Palisades Investment Partners LLC purchased a new position in Travere Therapeutics during the fourth quarter worth $5,264,000. Essex Investment Management Co. LLC purchased a new position in Travere Therapeutics during the third quarter worth $3,872,000. Lisanti Capital Growth LLC purchased a new position in Travere Therapeutics during the third quarter worth $3,095,000. Finally, Apis Capital Advisors LLC purchased a new position in Travere Therapeutics during the third quarter worth $3,967,000.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.